Compare Atlassian Corporation PLC (TEAM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs Viatris Inc — how do they compare? Atlassian Corporation PLC trades at $202.73 (market cap $49.56B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Atlassian Corporation PLC is far larger — about 2.5× Viatris Inc's market cap, and Viatris Inc pays a 2.74% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 64 Days and Viatris Inc for 57 Days on average.
| TEAM | VTRS | |
|---|---|---|
Market Cap | $49.56B | $20.12B |
Volume | 1,747,462 | 7,543,511 |
Sector | Technology | Health |
52-Week High | $203.57 | $18.27 |
52-Week Low | $57.15 | $9.74 |
Typical Hold Time | 64 Days | 57 Days |
Enterprise Value | $49.56B | $32.24B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $203.57, up 4.94% with strong technical momentum and bullish moving averages. The stock shows improving fundamentals with revenue growth from $5.22B in 2025 to projected $6.6B in 2026, though it remains unprofitable with a -0.82% net margin. Recent earnings beats and accelerating cloud/AI adoption drive positive sentiment, with analyst consensus strongly bullish at 70% buy ratings.
Outlook remains positive due to cloud migration progress and AI product adoption, but investors face valuation concerns with elevated P/S of 7.75 and EV/EBITDA of 233.57. Key risks include persistent profitability challenges and competitive pressures in enterprise software. Current price exceeds consensus target of $191.16, suggesting near-term consolidation potential.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
